Drug Approval | June 23, 2022
Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
Subscribe To Our Newsletter & Stay Updated
